TIL细胞治疗恶性胸水的疗效观察  

Observation of efficacy of tumor infiltrating lymphocytes in treatment of malignant pleural effusion

作　　者：陈建清[1] 曾道林[1] 康美玲[1] 钟小红[1] 董书春[1] 刘进兵[1] 吴晓安[1] 

机构地区：[1]解放军第一七四医院肿瘤中心二区,厦门361003

出　　处：《中国肿瘤临床与康复》2011年第1期56-57,共2页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的观察肿瘤浸润淋巴细胞(TIL)治疗恶性胸水的疗效。方法从30例恶性肿瘤胸水中的肿瘤细胞分离得到TIL,并经10%人AB血清RPM I-1640液培养,经rIL-2体外激活培养,随后胸腔注射。结果完全缓解12例(40.0%),有效15例(50.0%),无效3例(10.0%),总有效率90.0%(27/30)。结论 TIL治疗恶性胸腔积液疗效好,毒副作用小,能改善患者的生活质量。Objective To evaluate the efficacy of tumor infiltrating lymphocytes（TIL）in treatment of patients with malignant pleural effusion.Methods TILs derived from malignant pleural effusion of 30 patients were cultivated in 10% human AB type serum RPMI-1640 liquid medium,activated by rIL-2 in vitro and injected into thoracic cavities.Results CR 12（40.0%）,PR 15（50.0%）,NR 3（10.0%）.Conclusion The result suggests that TILs derived from malignant pleural effusion have good therapeutic efficacy and is safe in patients with malignant pleural effusion and can improve the quality of life of the patients.

关 键 词：恶性肿瘤 肿瘤浸润细胞 白细胞介素-2 胸腔积液 穿刺术 

分 类 号：R730.5[医药卫生—肿瘤]